Paperonium

Kidney transplants · Kidney Int · 2022

The paper reports 99% less COVID illness with the drug, outside its own 80–94% range.

The paper’s number99% less, outside its own rangeThe centre of that same range0.112, or 89% less0.011×0.063 to 0.198should be inside0.0630.1980.01×0.03×0.1×0.3×1×same ratetreated fall ill less
The paper’snumber99% less, outsideits own rangeThe centre ofthat same range0.112, or 89% less0.011×0.063 to 0.198should be inside0.0630.1980.01×0.05×0.2×1×same ratetreated fall ill less

Treated patients’ illness rate as a fraction of the untreated. Dot: estimate; bar: range.

The paper says

Among kidney transplant patients, the 333 given a preventive antibody drug fell ill with COVID 99% less often than the 97 untreated: 0.011 times their rate. The paper’s range of plausible values: 0.063 to 0.198, or 80% to 94% less often. 99% is outside it.

Its own data show

That range is centred on 0.112: it runs from 0.112 divided by 1.77 (0.063) to 0.112 times 1.77 (0.198). So the data point to about 89% less often. 0.011 is a tenth of 0.112, a gap rounding can’t explain. The paper’s other three numbers (hospital stays, intensive care, death) each sit at their range’s centre.

A range like this is made by multiplying and dividing the best estimate by one number, so the estimate always sits in its middle. Treated patients still clearly fell ill less often. But 0.011 puts their illness rate at about 1% of the untreated rate instead of about 11%, making protection look near-total.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders · Kidney Int (2022) · doi:10.1016/j.kint.2022.07.008